Business Wire

RIGHTMINDER

29.3.2017 08:02:54 CEST | Business Wire | Press release

Share
RightMinder – Leveraging the Everyday Smartwatch, Heralding New Opportunities for Aged Care

With the exponential growth of the aged care industry, cost and care issues are prevalent not only in the UK and Europe but globally. ConnectUs Life Pty Ltd, a specialist care-related services provider has launched RightMinder®, an app that leverages advancements in wearable technology and the increase in availability and use of affordable smartwatches. Coinciding with the release of Android Wear 2.0, RightMinder® caters to the elderly, those in need, pre-teens and Professional Carers. Available in multiple languages and in over 136 countries, RightMinder® delivers a patent-pending solution providing fall detection, first alert monitoring and alerts, GPS location reporting, and multiple first alert carer connections.

RightMinder® has been created to connect ‘wearers’ and ‘carers’. Ben Slater, ConnectUs Life CIO says, ”Our core focus is to ensure wearers maintain meaningful independence with an efficient, yet discreet safety and security alert system. Anyone can use RightMinder® without lock-in contracts, nor do they need expensive custom hardware.” Mr Slater says, “Our First Alert Carers are not only from the family & friends orientated network, but also paid professional Carers too.”

Whilst RightMinder® is specifically designed for Android smartwatches (for wearers), the First Alert and Fall Detection functionality is also available on the mobile phone itself, so anyone can use RightMinder® without requiring a smartwatch. However, RightMinder® strongly recommends using a smartwatch for safety and as a discreet alternative to “the big red emergency button” or pendant. Mr Slater says, “We are extremely encouraged by the acceptance of smartwatch technology amongst our focus groups. Wearers have embraced smartwatch technology when paired with the RightMinder® app. RightMinder® has proven to be very easy to use and manage, despite the underlying complexity of the algorithms utilised.”

RightMinder® wearers are securely connected to one or more carers who can then monitor battery life, location and access fast-touch call buttons. If a Wearer triggers a Fall Detection, or if they send an emergency First Alert, their carers all receive immediate notifications and emails to raise an emergency response. Carers then have the option to locate or call their wearers immediately. Additionally when battery life gets low, notifications are also sent to both wearer and carers.

RightMinder® also extends to people living with disabilities such as MS, dementia, brain trauma, epilepsy and for other high need individuals.

RightMinder® helps reduce the level of dependence on professional operators and on tax funded government assistance.

Contrary to the notion that technology can be complicated, RightMinder® is easy-to-use with a user-friendly interface that has been designed to benefit users who are wearers and carers. Alerting carers is now fast, simple and discreet for any RightMinder® wearer.

The convenience that comes with using the app, in addition to the affordability of the innovative concept, gives independence and empowerment to wearers and comfort to carers like never before, even if wearers and carers live countries apart.

RightMinder® aims for peace of mind without being front of mind.

RightMinder® is available on Google Play Store for Carers and Wearers and coming soon to the Apple App Store (for Carers).

For a full video of the app, please see https://www.youtube.com/watch?v=c2XF2YPabDc .

Contact:

RightMinder
Drew Steptoe, Joint MD and CEO.
+61 423 009 082
drew@connectus.life
or
Ben Slater, Joint MD and CIO.
+61 433 773 585
ben@connectus.life
www.connectus.life | www.rightminder.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye